Celgene's Lenalidomide Proves Promising in Ongoing DLBCL Trials

The phase 2 study combined lenalidomide with R-CHOP in newly diagnosed patients.

The combination of lenalidomide and R-CHOP demonstrated considerable activity in patients with newly diagnosed diffuse large B-cell lymphoma, according to results of a phase 2 study.

The development of a more effective initial therapy is essential to improve long-term outcomes of patients with diffuse large B-cell lymphoma (DLBCL), Grzegorz S. Nowakowski, MD, of the division of hematology at Mayo Clinic in Rochester, Minn., and colleagues wrote.

Prior studies demonstrated lenalidomide (Revlimid, Celgene) has considerable single-agent activity in relapsed DLBCL. Lenalidomide also can be combined with R-CHOP — which consists of rituximab (Rituxan; Genentech, Biogen Idec), cyclophosphamide, doxorubicin, vincristine and prednisone) — to form a novel combination known as R2CHOP.

In the current study, Nowakowski and colleagues evaluated the efficacy of R2CHOP in 60 patients with newly diagnosed DLBCL. The median age of patients was 65 years; 70% were aged older than 60 years, and 9% were aged ≥80 years.

Link to the complete article: http://bit.ly/1tT62kq

Source: Healio